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SUMMARY. Emerging data indicate that all-oral antiviral
treatments for chronic hepatitis C virus (HCV) will become
a reality in the near future. In replacing interferon-based
therapies, all-oral regimens are expected to be more tolera-
ble, more effective, shorter in duration and simpler to
administer. Coinciding with new treatment options are
novel methodologies for disease screening and staging,
which create the possibility of more timely care and treat-
ment. Assessments of histologic damage typically are per-
formed using liver biopsy, yet noninvasive assessments of
histologic damage have become the norm in some Euro-
pean countries and are becoming more widespread in the
United States. Also in place are new Centers for Disease
Control and Prevention (CDC) initiatives to simplify testing,
improve provider and patient awareness and expand rec-
ommendations for HCV screening beyond risk-based strate-
gies. Issued in 2012, the CDC recommendations aim to
increase HCV testing among those with the greatest HCV
burden in the United States by recommending one-time
testing for all persons born during 1945–1965. In 2013,
the United States Preventive Services Task Force adopted
similar recommendations for risk-based and birth-cohort-
based testing. Taken together, the developments in screen-
ing, diagnosis and treatment will likely increase demand
for therapy and stimulate a shift in delivery of care related
to chronic HCV, with increased involvement of primary
care and infectious disease specialists. Yet even in this new
era of therapy, barriers to curing patients of HCV will exist.
Overcoming such barriers will require novel, integrative
strategies and investment of resources at local, regional
and national levels.
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INTRODUCTION
The treatment landscape for hepatitis C is in flux. From
2002 to 2011, the standard of care treatment for chronic
infection with hepatitis C virus (HCV) was 24 or 48 weeks
of therapy with pegylated interferon-alfa (PEG-IFN) and
ribavirin (RBV). For patients with genotype 1 virus, the
likelihood of achieving a sustained virological response
(SVR), defined as having undetectable serum HCV RNA at
24 weeks after cessation of treatment, was only 40–50%
after 48 weeks of therapy. In 2011, the HCV protease
inhibitors telaprevir and boceprevir entered the market to
be used in combination with PEG-IFN and RBV for geno-
type 1 HCV infection. The protease inhibitors increase the
likelihood of SVR to 67–75% in treatment-na€ıve patients
with genotype 1 HCV [1–4]. However, adding a protease
inhibitor to a PEG-IFN backbone, which is itself difficult to
tolerate, has increased the potential for toxicity and has
placed a resource-intensive burden on treating physicians.
In addition, the triple therapy regimens have limited effi-
cacy in treatment-experienced null responders [5].
Several directly acting antiviral agents are being evalu-
ated for their potential use in combination with either RBV
or other antivirals of different classes. In early 2013, a
small study of the nucleotide sofosbuvir in combination
with RBV was reported, and among 25 treatment-na€ıve,
HCV genotype 1 patients, 21 (84%) had an SVR after
12 weeks of therapy [6]. In another small study reported
in early 2013, a total of 31 of 33 (94%) previously treat-
ment-na€ıve genotype 1 patients were HCV RNA negative
12 weeks after cessation of therapy with the NS3 protease
inhibitor ABT-450, combined with low-dose ritonavir, the
non-nucleoside NS5B polymerase inhibitor ABT-333 and
ribavirin [7]. In phase 3 studies of sofosbuvir with RBV,
SVR rates have been as high as 78% in HCV genotype 2
and 3 patients [8], and it is anticipated that in the United
States, all-oral combination therapies will be available for
HCV genotype 2 or 3 patients by 2014. By 2015, regimens
including only directly acting antivirals are expected to be
available for persons with any HCV genotype.
At this time of new treatment opportunities, novel
changes have been made to improve the methods by which
extent of liver disease is diagnosed. Assessment of the extent
of histologic damage, an important component of patient
evaluation, has been traditionally carried out by liver
biopsy. Noninvasive assessments of histologic damage such
as elastography have become the norm in several European
countries and are becoming more frequently used in the
United States. Strategies for HCV screening also have been
revised. To improve the identification of persons living with
chronic HCV infection, the U.S. Centers for Disease Control
and Prevention (CDC) expanded its risk-based approach to
HCV testing, publishing a recommendation in 2012 that all
persons born during 1945–1965 receive one-time testing
for HCV. In 2013, the United States Preventive Services
Task Force (USPSTF) adopted similar recommendations for
risk-based and birth-cohort-based testing. Growing evidence
suggests that in the United States, HCV infections are rap-
idly increasing among persons aged 15–24 primarily
because of injection drug use [9]. This trend suggests that
screening efforts should also ensure that young injection
drug users are tested and engaged in care.
The 2010 Patient Protection and Affordable Care Act
(ACA) will expand opportunities for persons to purchase
health insurance and have access to hepatitis C testing,
care and treatment. The ACA will facilitate implementation
of HCV testing because it requires nongrandfathered
private health plans to cover clinical preventive services
given an A or B grade by the USPSTF without cost-sharing
and provides incentives for Medicaid programmes to cover
these services. By prohibiting insurance companies from
declining to sell or renew policies because of pre-existing
conditions such as hepatitis C, ACA will help more patients
access HCV care and treatment services [10].
Improvements in therapies, diagnostic techniques and
screening for HCV will create a new era for HCV treat-
ment. Although the exact effects these changes will have
on the future landscape of HCV care cannot be elucidated,
certain outcomes are likely. For instance, as methods for
diagnosis of liver disease and treatment of HCV become
simpler, safer and more effective, primary healthcare pro-
viders may manage greater numbers of HCV-infected
patients. This expansion into primary care may become
necessary if the number of patients undergoing treatment
increases because of screening efforts and improved pros-
pects for treatment success for regimens containing all
directly acting antivirals. Also subject to change are pric-
ing and reimbursement models, as well as the pharmaco-
economics of curing HCV.
To discuss the new paradigm of HCV therapy, represen-
tatives from leading academic medical centres, government
agencies, insurance providers and the pharmaceutical and
biotechnology industries met in Boston, Massachusetts,
USA, on March 22 and 23, 2013. The focus of the meet-
ing, or Think Tank, was to predict how shifts in HCV
screening, diagnosis and treatment will affect access to and
delivery of care; identify barriers to treating HCV; discuss
successful strategies for identifying and treating patients;
and discuss the pharmacoeconomics of treatment for
patients, providers, pharmaceutical companies and health-
care payers. Here, we describe the current challenges and
opportunities for curing HCV in the forthcoming era.
CURRENT EVOLUTION OF ALL-ORAL THERAPIES
FOR HCV
Arrays of IFN-free regimens for treating HCV are currently
in the later stages of clinical development. At scientific
meetings, data have been presented from phase 2 and 3
studies of various all-oral regimens. The results of individ-
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ual studies will not be described in great detail here but
are summarized in Table 1. The more promising regimens
have the following characteristics: a strong safety profile,
SVR rates approaching or even exceeding 90%, minimal
pill burden and minimal potential for drug–drug interac-
tions.
Several major conclusions and predictions regarding the
future of all-oral therapies were discussed. A reasonable
Table 1 Reported results for all-oral therapies for hepatitis C virus in clinical development
No. patients Duration, weeks SVR rates Reference
Treatment-naïve patients
Genotype 1 (1a or 1b)
ABT-450/r + ABT-333 + RBV 33 12 94% SVR12 Poordad et al. [7]
ABT-450/r + ABT-267 + ABT-333 + RBV 80 8 88% SVR12 Kowdley et al. [11]
ABT-450/r + ABT-333 + RBV 41 12 85% Kowdley et al. [11]
ABT-450/r + ABT-267 + RBV 79 12 90% Kowdley et al. [11]
ABT-450/r + ABT-267 + ABT-333 79 12 87% Kowdley et al. [11]
ABT-450/r + ABT-267 + ABT-333 + RBV 79 12 98% Kowdley et al. [11]
Daclatasvir + Asunaprevir + BMS-791325 16 24 88% Everson et al. [98]
Daclatasvir + Asunaprevir + BMS-791325 16 12 94% Everson et al. [98]
Faldaprevir + Deleobuvir 46 28 39% SVR12 Zeuzem et al. [15]
Faldaprevir + Deleobuvir + RBV 316 16, 28, or 40 52–69% SVR12 Zeuzem et al. [15]
Mericitabine + Danoprevir + RBV 64 24 71% SVR12 Gane et al. [99]
Sofosbuvir + RBV 25 12 84% Gane et al. [6]
Sofosbuvir + Daclatasvir 55 12 or 24 98% SVR4 Sulkowski et al. [14]
Sofosbuvir + Daclatasvir + RBV 56 12 or 24 96% SVR4 Sulkowski et al. [14]
Sofosbuvir + Ledipasvir + RBV 25 12 100% SVR12 Gane et al. [100]
Genotype 2 or 3
Sofosbuvir + RBV 10 12 100% Gane et al. [6]
Sofosbuvir 10 12 60% Gane et al. [6]
Sofosbuvir + RBV 253 12 67% SVR12 Gane et al. [101]
Sofosbuvir + Daclatasvir 14 24 100% Sulkowski et al. [14]
Sofosbuvir + Daclatasvir + RBV 14 24 93% Sulkowski et al. [14]
Prior nonresponse
Genotype 1 (1a or 1b)
ABT-450/r + ABT-333 + RBV 17 12 47% SVR12 Poordad et al. [7]
ABT-450/r + ABT-267 + RBV 45 12 89% Kowdley et al. [11]
ABT-450/r + ABT-267 + ABT-333 + RBV 45 12 93% Kowdley et al. [11]
Daclatasvir + Asunaprevir 11 24 36% Lok et al. [102]
Sofosbuvir + RBV 10 12 10% Gane et al. [6]
Sofosbuvir + Daclatasvir 21 12 100% Sulkowski et al. [13]
Sofosbuvir + Daclatasvir + RBV 20 12 95% Sulkowski et al. [13]
Sofosbuvir + Simeprevir + RBV 27 12 96% SVR8 Lawitz et al. [12]
Sofosbuvir + Simeprevir 14 12 93% SVR8 Lawitz et al. [12]
Sofosbuvir + Ledipasvir + RBV 10 12 100% SVR12 Gane et al. [100]
Genotype 1b
Daclatasvir + Asunaprevir 21 24 91% Suzuki et al. [103]
Genotype 2 or 3
Sofosbuvir + RBV 201 12 or 16 SVR12
12 week: 50%
16 week: 73%
Jacobson et al. [8]
IFN-ineligible or intolerant
Genotype 1b
Daclatasvir + Asunaprevir 22 24 64% Suzuki et al. [103]
Genotype 2 or 3
Sofosbuvir + RBV 207 12 78% SVR12 Jacobson et al. [8]
ABT-450/r, ritonavir-boosted ABT-450; IFN, interferon; RBV, ribavirin; SVR, viral negativity 24 weeks post-therapy.
SVR12, SVR8 and SVR4 refer to viral negativity at 12, 8 and 4 weeks post-therapy.
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anticipation is that a genotype-specific, all-oral therapy for
HCV genotypes 2 and 3 with sofosbuvir and ribavirin will
be available by 2014. By 2015, genotype-1-specific
therapies should follow, and these will comprise any of
three regimens currently under development by AbbVie
Pharmaceuticals, Bristol-Myers Squibb and Gilead Sciences
(Table 1). True pangenotypic regimens will probably not be
available until 2016 or 2017 and will require development
of pangenotypic NS5A inhibitors and protease inhibitors
that can be combined with each other and with nucleotide
polymerase inhibitors. Some of these combinations are in
phase 1 or early phase 2 studies across multiple genotypes.
Another major area of discussion was whether pretreat-
ment and on-treatment predictors of response, including
those used for PEG-IFN, can help predict response to all-
oral therapies. Although there is evidence that many of
these factors still predict response to relatively weak inter-
feron-sparing regimens, more potent regimens, with SVR
rates >90%, readily overcome the traditional obstacles seen
with PEG-IFN. For example, in phase 2 studies of the
Abbott multidrug regimen [11] or sofosbuvir plus simepre-
vir [12] or daclatasvir [13], prior interferon response was
not strongly related to response to all-oral treatment. In
fact, interferon null responders did just as well as na€ıve
patients and had SVR rates in the 90% range. It is increas-
ingly apparent that regimens consisting of potent agents
that individually or cumulatively impose a high barrier to
resistance attenuate or eliminate factors such as 1a/1b
subtype, IL28B status, viral load, race, metabolic syn-
drome, obesity and age as major determinants of response.
In addition, with potent directly acting antiviral combina-
tions, nearly all patients are negative within 4 weeks,
which means the traditional strategy of using virologic
response at week 4 or 12 to determine the duration of
treatment may be moot. The presence of cirrhosis, which
often excludes patients from early phase trials, may yet be
a differentiating factor in SVR rates, but this remains to be
further determined for genotype 1, and as with other fac-
tors, presence of cirrhosis can probably be overcome by a
sufficiently potent regimen or longer treatment duration.
In studies of sofosbuvir and RBV in patients with HCV
genotypes 2 or 3, cirrhosis was a significant negative pre-
dictor of response for treatment-na€ıve patients with HCV
genotype 3 and for prior treatment-failure patients with
either genotype 2 or 3, but these studies only included 1
potent directly acting antiviral. The effect of portal hyper-
tension and hepatocellular dysfunction (Child’s class B and
C) on SVR in patients with more advanced liver disease
remains an area requiring additional investigation.
The final major questions for discussion encompassed
the need for RBV and duration of therapy, which are in
some ways connected. As with the pretreatment predictors,
ribavirin use and treatment duration appear to matter with
relatively weak regimens but may not with sufficiently
potent combinations. In studies of the polymerase inhibitor
sofosbuvir with either the NS5A inhibitor daclatasvir [14]
or the protease inhibitor simeprevir [12], SVR rates were
independent of RBV use. However, in a study combining
the protease inhibitor faldaprevir and the non-nucleoside
polymerase inhibitor deleobuvir, omitting RBV resulted in
a marked reduction in efficacy in genotype 1a patients
[15]. And for HCV genotype 1a patients in the phase 2
AVIATOR trial [11], the removal of RBV from a regimen
containing the ritonavir-boosted protease inhibitor
ABT-450/r, the NS5A inhibitor ABT-267 and the non-
nucleoside polymerase inhibitor ABT-333 resulted in a
10% loss of efficacy. The optimal duration of therapy
remains unknown, but with potent regimens, 12 weeks is
probably the maximum required for most patients (with
the potential exception for patients with advanced cirrho-
sis). Eight-week treatment regimens can be explored,
although this may result in a moderate (~10%) reduction
in SVR [11] depending on the regimen.
For regimens containing only direct-acting antivirals,
one could imagine a scenario where more potentially diffi-
cult-to-treat patients are distinguished from a potentially
more easily treatable population. Difficult-to-treat patients
may be best served by undergoing an individualized regi-
men under the care of a specialist. Individualized therapy
could be based upon HCV genotype, fibrosis stage, comor-
bidities, concomitant medications or prior directly acting
antiviral drug exposure. Populations of patients who may
require individualized therapy but for whom evidence-
based treatment data are limited include those with cirrho-
sis, including decompensated cirrhosis, HIV coinfection,
renal failure, an organ transplant or other conditions
resulting in being immunocompromised. In the future, it is
possible that the population of HCV positive individuals
with F0-2 histology will undergo treatment without further
stratification such as via HCV genotype or IL28B polymor-
phisms, because SVR rates will likely be in the 90% range.
SCREENING STRATEGIES FOR HCV
In the United States, mortality associated with hepatitis C
is on the rise and currently exceeds that for HIV [16]. On
the basis of survey data from 1999 to 2002, it has been
estimated that 3.2 (2.7–3.9) million persons in the United
States have chronic HCV infection [17]. The strongest risk
of HCV infection is a history of injection drug use [17]. Of
persons with chronic infection, 74% were born during the
years 1945 through 1965 [18].
In 1998, CDC recommended a risk-based approach to
screening, with routine HCV testing for persons with risk
factors including injection drug use, having received clot-
ting factor concentrates produced before 1987, being on
chronic haemodialysis, having persistently abnormal ala-
nine aminotransferase levels, being a recipient of donated
blood from a person who tested positive for HCV, or having
received a blood transfusion or organ transplant before
© 2013 The Authors. Journal of Viral Hepatitis published by John Wiley & Sons Ltd
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July 1992 [19]; in 1999, CDC recommended HCV testing
for persons with HIV. The 2009 guidelines from the Amer-
ican Association for the Study of Liver Diseases (AASLD)
[20] and the 2006 guidelines from the American College
of Gastroenterology [21] also recommend screening in
high-risk patients. However, risk-based screening strategies
can be limited either by clinician reluctance to ask about
risk factors or by patient unawareness or reluctance to dis-
close risk behaviours. As a result, use of risk-based strate-
gies alone has resulted in a large proportion of infected
persons remaining undiagnosed; in the United States, vari-
ous estimates indicate that 45–85% of persons with HCV
are unaware of their infection status [22–25]. To augment
risk-based screening, in 2012 CDC published a recommen-
dation for one-time testing without prior ascertainment of
HCV risk for persons born during 1945–1965 [25]. This
birth-cohort approach was designed to both target persons
with the highest prevalence of HCV infection and remove
any behavioural stigma from screening. In the state of
New York, legislation requiring all patients born within
the birth-cohort period to be offered hepatitis C screening
when they visit healthcare providers has passed the legisla-
ture and is awaiting the governor’s approval.
It has been estimated that with implementation of the
birth-cohort screening strategy, 121 000 deaths from HCV
will be averted [26]. In recognition of these and other data
[27,28], in June 2013 the USPSTF issued a final recom-
mendation regarding HCV testing, assigning a Grade B to
two recommendations: screening for HCV infection in per-
sons at high risk for infection and one-time HCV screening
for adults born between 1945 and 1965 [29]. A USPSTF
Grade B designation expands access to clinical preventive
services.
For HCV screening to become widely adopted in diverse
clinical settings providing care for persons at risk for HCV
infection, efforts are needed at local, regional and national
levels. Approximately 79 million persons were born during
1945–1965 (the Baby Boom Generation), making birth-
cohort based screening a daunting task. However, since
the release of the CDC recommendations, multiple indepen-
dent studies of HCV testing have shown birth-cohort-based
approaches superior to risk-based strategies alone [30,31].
To increase the numbers of HCV-infected persons aware of
their infection, CDC is implementing a national multimedia
campaign, Know More Hepatitis, that includes education
for consumers and healthcare providers (http://www.cdc.
gov/knowmorehepatitis/). Specific initiatives include mes-
saging on airport dioramas and billboards in cities such as
Atlanta, Washington, DC, Salt Lake City, Orlando and Las
Vegas; online medical education for health professionals
(http://depts.washington.edu/hepstudy/hepC/); and the
launch of an annual National Hepatitis Testing Day
observed on May 19th.
Centers for Disease Control and Prevention is also con-
ducting demonstration projects to evaluate the implemen-
tation of risk-based and birth-cohort strategies for HCV
strategies in over 25 clinical settings. For example, the
Hepatitis C Assessment and Testing Project in New York
City evaluated community-based screening interventions in
three urban primary care clinics [32]. Both risk-based and
birth-cohort-based interventions were associated with an
increased proportion of patients tested for HCV. Both risk-
based and birth-cohort HCV screening approaches can be
integrated within electronic medical records.
The new HCV screening recommendations are expected
to increase demand for testing to detect current HCV infec-
tion. To meet this demand, CDC recently simplified the
HCV testing sequence [33]. Patients should first be tested
for HCV antibody. Patients who are reactive for HCV anti-
body should next be tested with an FDA-approved nucleic
acid testing assay for the detection of HCV RNA indicative
of current HCV infection. Rapid tests for HCV antibody
allow access to HCV testing in settings lacking laboratory-
based diagnostic services. Rapid tests for HCV antibody
detection include OraQuick [34], which is approved by the
United States Food and Drug Administration (FDA), as well
as Chembio [34,35], MedMira [34,35] and mBio, which
are under development.
HCV DIAGNOSTIC TESTING AND DISEASE
STAGING
It is likely that the rapid improvements in treatment effi-
cacy and tolerability anticipated with interferon-sparing
regimens will also transform our approach to disease stag-
ing. The historic low efficacy and safety of interferon-
based regimens led to the recommendation for liver stag-
ing to determine whether the benefits of treatment would
outweigh the risks. For most patients, this required that
there be more than just portal fibrosis. Liver biopsy was
considered the best test for this purpose, but the proce-
dure is costly, invasive and in a small minority of cases
can result in complications such as significant bleeding,
organ puncture, or death [36]. And the accuracy in stag-
ing disease is often compromised by variability in tissue
sampling or in interobserver or intra-observer histopatho-
logical scoring.
As treatment efficacy for genotype 2 and 3 infections
improved, biopsy was no longer routinely recommended to
justify treatment necessity [20]. Likewise, continued
improvements in treatment efficacy and safety for all geno-
types will change the primary goal of staging from justifi-
cation of treatment benefit to identification of persons with
cirrhosis or bridging fibrosis because they may need longer
treatment courses and require hepatocellular carcinoma
screening and portal hypertension management. Accord-
ingly, the most important characteristic of a staging test is
the negative predictive value for detection of cirrhosis.
Noninvasive methods of assessing histology are becom-
ing more widely used. These include measurement of
© 2013 The Authors. Journal of Viral Hepatitis published by John Wiley & Sons Ltd
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serum biomarkers of fibrosis and measurement of liver stiff-
ness through elastography (Table 2). The noninvasive
methods have practically no complications and can be per-
formed repeatedly to dynamically monitor progression of
fibrosis. The rate of adoption of noninvasive diagnostic
tests for liver fibrosis differs between international regions,
and the United States lags behind Europe in this regard.
The 2012 European Association for the Study of the Liver
(EASL) guidelines for treating chronic hepatitis C suggest
that while liver biopsy is still regarded as the reference
method for grading inflammation and staging fibrosis,
transient elastography can be used to assess liver fibrosis,
and noninvasive serum markers are recommended for
detecting significant fibrosis (METAVIR score F2-F4) [37].
In 2004, the biomarker assay FibroSure (named Fibro-
Test in Europe) was launched in the United States for
assessing fibrosis and necroinflammatory activity. The
assay, which can only be performed in validated laborato-
ries, predicts a histology score on the basis of patient age,
sex and results for serum haptoglobin, a2-macroglobulin,
apolipoprotein A1, c-glutamyltransferase and bilirubin
analyses [38]. In a review of 25 studies in chronic HCV,
FibroTest had an AUROC of 0.79 (0.70–0.89) for diagnosis
of significant fibrosis (F ≥ 2) and 0.86 (0.71–0.92) for liver
cirrhosis [38].
If the birth-cohort screening to enhance diagnosis of
HCV infection is fully implemented, it has been estimated
that as many as 800 000 additional cases of HCV infection
would be identified [26]. Should there be such a large-scale
influx of newly diagnosed patients, tests of serum biomar-
kers will likely be a more practical approach to liver dis-
ease staging than one restricted to liver biopsy-based
staging. In the United States, the FibroSure test costs
approximately $250, which is a fraction of the cost of
biopsy. The biomarker assay AST-to-Platelet Ratio Index
(APRI) is not proprietary and costs no more than a routine
blood draw and routine liver function tests. APRI is calcu-
lated as (AST/upper limit of normal range)/platelet count
(109/L) 9 100. However, a recent large meta-analysis sug-
gested that APRI can identify hepatitis C-related fibrosis
with only a moderate degree of accuracy (AUROC of 0.77
for significant fibrosis and 0.80 for severe fibrosis) [39].
Alternate in vitro diagnostic testing for liver fibrosis was
subsequently developed, including FibroIndex and Forns
index [38]. For identifying cirrhosis, the age-platelet index,
APRI and Hepascore have median AUROCs of 0.80 or
greater (range 0.80–0.91) [38].
Transient elastography, using the FibroScan device
(Echosens, Paris, France), is widely used in several Euro-
pean countries and has more recently been adopted in Asia
and Canada. In April of 2013, FibroScan was approved by
the FDA for use in the United States. The main limitation
of FibroScan use in practice is its limited applicability
(80%), mostly due to patient obesity or limited operator
experience [40]. Results of a meta-analysis suggest Fibro-
Scan is a reliable method for diagnosing significant fibrosis
(AUROC = 0.84), severe fibrosis (0.89) and particularly cir-
rhosis (0.94) [41]. However, for diagnosing significant
fibrosis, a high variation of the AUROC was found depend-
ing on the type of underlying liver disease [41]. When
compared and validated externally in a multicenter pro-
spective study, FibroScan outperformed serum biomarkers
of fibrosis for the prediction of cirrhosis (AUROCS 0.89–90
vs 0.77–0.86) but had similar performance for the diagno-
sis of significant fibrosis [42]. Both FibroScan and FibroTest
have a prognostic value similar to liver biopsy for predict-
ing complications and outcome of liver disease [43,44].
Combining FibroScan with Fibrotest may increase diagnos-
tic performance for significant fibrosis [45,46], and this
approach has been recommended in the 2012 EASL Guide-
Table 2 FibroScan and FibroSure* for diagnosis of cirrhosis
FibroScan FibroSure
AUROC, mean (95% CI) 0.94 (0.93–0.95) [41] 0.86 (0.71–0.92) [38]
Sensitivity (95% CI) 0.83 (0.79–0.86) [104] 0.85 [38]
Specificity (95% CI) 0.89 (0.87–0.91) [104] 0.81 [38]
Advantages Evaluates a genuine property of the liver Good reproducibility
High performance for cirrhosis High applicability (>95%)
User-friendly, point-of-contact test
Good reproducibility
Disadvantages Decreased performance in obese patients Nonspecific of the liver
Applicability lower than serum biomarkers:
failure in 3% of cases and unreliable results
in 16% (obesity, ascites, limited operator experience)
Requires a dedicated device
Inflammation, extra-hepatic cholestatis, and
right heart failure can provide false positive results
*Known as FibroTest in Europe.
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lines as first line evaluation of liver fibrosis in patients with
chronic hepatitis C [37].
The Think Tank recognized that the goals of liver stag-
ing are changing and that there is an urgency to revise
guidelines accordingly. The accurate exclusion of cirrhosis
has been recommended as the most important role for
HCV staging in clinical practice, and an algorithm has
been proposed on how to best utilize noninvasive tests to
achieve this goal [47].
BARRIERS TO CARE AND STRATEGIES TO
ADDRESS THEM
Among persons infected with HCV, a substantial portion
fails to progress towards a cure at every step of treatment,
from recognition of disease to viral clearance (Fig. 1) [48].
In the United States, at least half of those infected with
HCV do not know their status [22–25]. Among patients
who are recognized as being positive for HCV antibody, it
is estimated that fewer than half are linked to care [49].
Failure to link to care represents both a lack of referral to
a specialist for treatment and failure to attend the appoint-
ment. Even after being linked to proper caregivers, patients
can fail to receive pretreatment work-up, meet eligibility
criteria for treatment or agree to initiate treatment.
Reasons for these failures can be attributed to barriers at
the level of patients, providers and the healthcare system
itself. Patients can have limited access to health care,
because of lack of or limited insurance [50], low health lit-
eracy or not having a usual source of medical care. They
can also have competing health priorities, such as mental
health issues [51] or comorbidities [52]. Issues related to
patient behaviours or environment, such as substance
abuse [53,54], lack of drug treatment, lack of social support
[55] or unstable employment or housing [56], may also
limit uptake of treatment. Patients may also have limited
knowledge of HCV and its treatment and may not perceive
it as being something they need to worry about because the
disease is largely asymptomatic [57]. Finally, many patients
fear the side effects of IFN-based regimens [57].
Primary care providers can have misconceptions about
whom to screen, risk of progression of liver disease or
ztherapy itself [58,59]. Even specialists in liver disease may
have limited experience treating HCV [60]. Providers also
can be selective about which patients they consider as
good candidates for therapy and fail to recommend treat-
ment because of concerns about nonadherence, drug use
[61] or risk of re-infection.
Governments and payers play key roles in delivering
HCV services; surveying infection, testing and treatment
rates; and educating the public and as well as healthcare
providers. Unfortunately, the United States has poorly
developed surveillance systems, inadequate educational ini-
tiatives and fragmented viral hepatitis services [62]. Also
at issue are insufficient numbers of providers who can and
are willing to treat HCV [63] and insufficient resources for
case managers, navigators and social workers.
Training community-based healthcare providers to treat
HCV may become a key method for broadening access to
cure. Community-based health centres often have advanta-
ges of being culturally appropriate and accessible to
patients in both urban and rural areas. In these settings,
ongoing relationships with providers may establish trust
and an avenue for communication. The Extension for Com-
munity Healthcare Outcomes model was developed as a
means of using video-conferencing to train primary care
providers through interactions with specialists to treat
complex diseases, such as HCV. In New Mexico, the pro-
gramme was successful in generating rates of SVR at 21
sites in rural areas and prisons that were similar to rates
Fig. 1 The hepatitis C care cascade. Among patients infected with hepatitis C virus, fewer than 10% are treated and cured.
Barriers exist in screening methods, patient referral to appropriate providers, attending necessary appointments and
initiating treatment [49,53,54,61,74,75,105–113].
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of SVR at the University of New Mexico’s HCV clinic [64].
Other strategies to improve rates of initiation and comple-
tion of therapy include having peer navigators and inte-
grated care programmes.
The Think Tank believed that screening in conjunction
with an all-oral treatment paradigm would reduce the bar-
riers to care and allow treatment within primary care and
community sites for many HCV-infected patients.
PHARMACOECONOMICS OF HEPATITIS C
The sequelae of hepatitis C impose a high economic bur-
den. It has been estimated that in 2012, the healthcare
cost of HCV was $6.5 billion, and it has been predicted the
cost will peak at $9.1 billion in 2024 [65]. A retrospective
analysis of data from a large, managed care organization
claims database suggested that the annual all-cause medi-
cal costs of patients diagnosed with HCV were almost twice
as high as enrollees without diagnosed HCV [66]. The
health burden of HCV largely relates to the development of
advanced liver disease, which can lead to liver transplant.
In the United States, HCV is the leading cause of hepatocel-
lular carcinoma [67], and it is likely that more cases of
hepatocellular carcinoma, decompensated cirrhosis and
liver transplants due to HCV will be observed in the com-
ing years [68]. The medical cost of hepatocellular carci-
noma has been estimated as $23 755–44 200 per year
per person, and the cost of liver transplant has been esti-
mated as $201 110 per year per person [69]. Additional
disease burden and costs are generated by extrahepatic
manifestations of HCV infection including cryoglobulinemic
vasculitis, lymphoproliferative disorders, renal disease and
rheumatoid-like polyarthritis [70].
The addition of telaprevir or boceprevir to PEG-IFN plus
RBV has changed the pharmacoeconomics of treating
HCV. Adding the directly acting antivirals to PEG-IFN and
RBV can increase the cost of treatment up to $50 000,
depending upon individual regimens needed [71], yet the
antivirals also increase the success rates of therapy. At
present, economic evaluations of telaprevir or boceprevir
with PEG-IFN and RBV are limited. A decision analysis of
telaprevir and boceprevir indicated that triple therapy
including telaprevir or boceprevir was cost-effective when
compared with dual PEG-IFN and RBV therapy in patients
with genotype 1 infection [72], although the results were
dependent on the cost of protease inhibitors, treatment
adherence rates and extent of fibrosis. More recently, a
study from Mount Sinai in New York has estimated that
the real cost of reaching end of therapy with triple therapy
may be as high as $147 000 when the cost of side effect
management is included [73].
As new all-oral regimens enter the market, several fac-
tors will affect their cost-effectiveness: success rates in
patients with advanced liver disease or difficult-to-treat
HCV genotypes, costs related to monitoring and managing
treatment-related toxicities, extent of clinically relevant
viral resistance and duration of therapy. The costs of new
agents will also be considered against the costs of current
IFN-based therapy, which is challenging to administer and
has side effects requiring ongoing management. The domi-
nant factor in cost assessments of treatment should be the
efficacy of the treatment because all those who fail experi-
ence most or all of the cost and none of the benefit. But
high projected costs of new directly acting antiviral
treatments may result in lack of access for some patients.
Industry-created assistance and co-pay programmes can be
instrumental in making treatment more affordable and
accessible. Public health programmes to support engaging
HCV-infected persons in care should also be explored to
provide infrastructure for wrap-around services that may
not be reimbursable (e.g. coordination of care or peer sup-
port). Given the projected high costs of treatment, rela-
tively minor investments in patient support mechanisms
are easily justified but not often implemented because of
the nature of the fee-for-service healthcare delivery system
in the United States. Enhanced communication between
physicians and third-party payers may increase the avail-
ability of new therapies to patients.
SPECIAL POPULATIONS
Patients with drug addiction
The majority of prevalent and incident infections of HCV
occur among injection drug users. Surveillance data have
provided evidence that among persons aged 15–24 years,
injection drug use is causing a rapid increase in HCV infec-
tions [9]. The increase appears to be occurring predomi-
nantly in non-Hispanic white males and females. More
effort is needed to better understand this trend and to
ensure that young injection drug users are tested and
engaged in care.
Fewer than 20% of drug users with HCV initiate antivi-
ral therapy [49,54,74,75], principally because of lack of
knowledge about HCV, an exaggerated concern about
treatment-related side effects and a low perceived need for
treatment. There has been reluctance among many health-
care providers to treat drug users because of concerns
about adherence, potential reinfection even if SVR is
attained, and overall lack of experience and consequent
discomfort with the care of patients with addiction prob-
lems. Despite concerns regarding adherence to HCV treat-
ment, results of a recent meta-analysis suggest that
treatment completion rates among drug users who initiate
therapy are over 80% [76]. Addiction treatment and sup-
port services (including peer support) increase HCV treat-
ment completion rates [77–80]. Multidisciplinary models
for the management of HCV among people who inject
drugs have been described in community-based clinics,
substance abuse treatment clinics and hospital-based clin-
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ics [79,81–83]. For example, integrating internist-addiction
medicine specialists from a methadone maintenance treat-
ment programme into a hepatitis clinic improved adher-
ence with HCV evaluation and treatment relative to
standard referral practices in patients with prior or ongo-
ing drug use [78]. Education of both patients and providers
about the disease and close collaboration between HCV
treaters and those who treat addiction are important ele-
ments to promote successful treatment of this patient
population. Evidence-based international recommendations
for treating hepatitis C in people who inject drugs were
recently released [84].
As HCV treatment shifts to all-oral regimens, wider
uptake among drug users is likely to occur because of
decreased side effects, elimination of mental illness as an
exclusion for therapy and elimination of needle exposure
during therapy. As suggested by modelling data, even
modest increases in the numbers of active injection drug
users who receive treatment may interrupt HCV transmis-
sion enough to result in substantial declines in HCV preva-
lence [85,86]. If the modelling data are verified by field
studies, timely HCV detection and treatment and their inte-
gration with other services for drug addiction will take on
new urgency. The Think Tank emphasized the need for
interventions that facilitate access to HCV therapy for drug
users, such as promoting HCV treatment among addiction
medicine specialists. In clinical studies of novel therapies,
exclusion criteria often limit participation of patients with
a history of injection drug use, even if patients have not
been using for a long time. Broadening criteria to include
such patients would better inform efficacy of treatment in
this population.
Patients with cirrhosis
Diagnosis of cirrhosis in patients with HCV is important in
part because these patients have a higher incidence of hepa-
tocellular carcinoma and a potential for bleeding from
oesophageal varices. Screening for each of these may result
in reductions in morbidity and mortality. Although the pres-
ence of cirrhosis decreases the likelihood of response to cur-
rent triple therapy regimens and increases the risk of side
effects [87], its presence does not rule out the possibility of
initiating therapy. Patients with compensated cirrhosis
(Childs-Pugh A) may be candidates for triple therapy if they
have well-maintained hepatic synthetic function and no
complications of portal hypertenstion (as assessed by serum
albumin and platelets). Indeed, treatment has traditionally
been considered strongly indicated in well-compensated
cirrhosis to prevent further disease progression or decom-
pensation. In contrast, patients with decompensated cirrho-
sis (Childs-Pugh B or C) are no longer considered candidates
for receiving current triple therapy regimens. Some of the
newer regimens have demonstrated promising rates of
efficacy for patients with cirrhosis [88,89]. The most exten-
sively studied oral regimen, with data from a phase 3
programme, is sofosbuvir and ribavirin in patients with
genotypes 2 and 3, in which cirrhosis had an impact in
patients with genotype 3 that may be ameliorated with
longer duration of therapy [8]. With the proliferation of
novel drugs and regimens under investigation, studies are
needed to address issues such as the pharmacokinetics and
pharmacodynamics in the setting of cirrhosis; tolerability
and efficacy across Childs-Pugh A, B and C patients; and
impact of SVR on clinical outcomes. Drug–drug interactions,
especially in post-transplant patients, must also be evalu-
ated. There is an urgent need for these issues to be addressed
as early in drug development programmes as possible.
Patients with HCV–HIV coinfection
Persons with HIV infection have a high prevalence of
chronic HCV infection with a tendency towards more rapid
progression to cirrhosis and potentially less access to liver
transplantation. Some reports suggest that relative to HCV
mono-infected patients, HIV-HCV coinfected patients also
have higher rates of comorbid conditions such as drug use,
major depression and anaemia [90]. With HIV therapies,
drug interactions may occur and may be difficult to pre-
dict; therefore, novel direct antiviral therapies for HCV will
need to be evaluated for their potential for interaction with
at least some HIV antiretrovirals. Coinfected patients have
reduced rates of response to therapy with PEG-IFN and
RBV [91], but adding telaprevir or boceprevir increases effi-
cacy of therapy [92,93]. Some of the newer regimens may
have even greater efficacy [94,95]. Curing HCV in coinfect-
ed patients is linked to improved clinical outcomes and
longer survival [93,96]. Conducting studies of the newer
regimens in coinfected patients will be important for gener-
ating data needed to develop practice guidelines and justify
third-party payment.
PRIORITIES FOR EDUCATION AND RESEARCH
Although all-oral therapies are likely to be simpler to
administer than IFN-based therapies, educating patients
and providers will remain a challenge. Both patients and
providers need to receive clear messages on the natural his-
tory of HCV, with warning signs and an explanation of
why diagnosis and treatment is important. Providers will
need to be educated regarding best practices for screening,
diagnosis and treatment. Partnerships between members of
academia, community health centres, the HCV-affected
community, the pharmaceutical industry, healthcare pay-
ers and federal, state, and local government entities are
very useful for performing postmarketing studies and edu-
cation (Table 3). One example is the CDC Foundation’s
Viral Hepatitis Action Coalition (http://www.viralhepatitis-
action.org/).
Updated treatment guidelines serve as a valuable
resource for providers and also influence payer policies. The
most recent guidelines for diagnosing, managing and
© 2013 The Authors. Journal of Viral Hepatitis published by John Wiley & Sons Ltd
New paradigm of hepatitis C therapy 753
treating hepatitis C in the United States were published by
the AASLD in 2009 [20], before FDA approval of telaprevir
and boceprevir. A 2011 update revised treatment recom-
mendations for patients with HCV genotype 1 [97], yet the
approach to testing and staging was not reassessed. Expert
opinion pieces can be helpful when guidelines are outdated
and should be considered as a means to provide guidance
in a rapidly changing field. In July 2013, the AASLD and
Infectious Diseases Society of America announced a collabo-
ration to develop clinical recommendations for managing
hepatitis C. To serve the medical community in the next
few years, one can anticipate a need for much more fre-
quent revisions by the professional societies to keep pace
with the evolution of a diverse group of therapies. The more
nimble and rapid methods for updating guidelines in HIV
could inform processes for updating guidelines in HCV.
Research in HCV should include evaluations of screen-
ing, care and therapy in community healthcare clinics,
drug treatment programmes and other settings providing
care to persons at risk for HCV infection. Improved and
expanded disease surveillance throughout the country is
indicated to better understand trends in transmission and
diagnosis. Serum biomarker assays to identify patients
likely to achieve a successful treatment outcome early on
should be incorporated into ongoing clinical trials of novel
therapies. As novel approaches towards screening and
treatment are developed, especially in rural or underserved
settings, it will be important that outcomes be reported so
that successful strategies can be imparted to others.
To understand the effects of cure on long-term health
outcomes, endpoints other than SVR should be evaluated
in clinical studies, and this is particularly true for confir-
mation of a reduction in the risk of development of hepato-
cellular carcinoma, liver failure and liver-related and
overall mortality in patients with cirrhosis. Registries care-
fully noting those who achieved viral eradication would be
useful for charting areas of success as well as ongoing
need. Such registries may also be helpful in identifying less
frequent side effects not noted in the registration trials as
well as outcomes in specific patient subgroups.
CONCLUSIONS
We have outlined the many challenges that lie ahead for
healthcare providers as we attempt to reverse the rising
morbidity and mortality associated with HCV. The new
opportunities afforded by screening and improved diagnos-
tics, education and treatment have created great excite-
ment both in the medical community and in our patients,
and the opportunities raise the prospect of eradicating
HCV-related liver disease and eventually transmission. In
the United States, HCV has all the attributes of an eradica-
ble disease except sufficient public investment. Delivering
care effectively, safely and broadly to all patient popula-
tions in an economically acceptable fashion must be our
goal now and over the next 5–10 years.
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